Aarti Drugs Limited

Aarti Drugs Limited

504.15
INR
+2.35
(+0.47%)
25.06EPS
17.17P/E
39.30BMarket Cap
Jan 27Next Earn
Aarti Drugs Limited
BSE:AARTIDRUGS
(Bombay Stock Exchange)

Recent

price

504.15

P/E

ratio

17.17

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
51.25
68.06
85.15
100.13
112.96
117.16
125.24
131.84
165.48
193.79
231.2
268.75
292.18
272.9
259.55
276.24
312.37
Revenue per Share
2.32
2.32
4.67
6.37
7.98
7.09
8.57
8.73
9.51
15.17
30.09
22.14
17.96
18.65
18.42
21.36
25.07
Basic EPS, GAAP
-4.1
-0.29
1.27
-1.15
-0.25
3.47
6.91
-0.51
7.3
21.75
7.16
-8.81
-3.4
14.42
7.39
8.79
- -
Free Cash Flow per Basic Share
0.94
0.56
1.13
1.44
2.34
2.44
- -
0.26
0.26
0.75
2.49
1.03
1.02
1.01
0.99
1.99
- -
Dividend per Share
15.64
18.22
21.43
25.9
31.81
35.79
41.93
48.28
58.31
70.01
98.01
111.92
128.77
139.4
149.99
169.7
184.24
Book Value per Share
14.67
16.91
20.62
25.58
31.68
35.01
41.29
47.8
58
69.85
97.98
111.9
126.15
135.39
143.07
157.78
182.46
Tangible Book Value per Share
97
97
97
97
97
97
95
94
94
93
93
93
93
92
91
91
91
Basic Weighted Avg Shares
4,964
6,593
8,248
9,699
10,943
11,349
11,952
12,436
15,609
18,061
21,548
24,886
27,056
25,089
23,689
25,213
28,510
Sales/Revenue/Turnover
9.64
8.92
12.05
12.86
12.87
13.39
13.17
13.31
10.95
12.35
18.37
11.97
9.84
11.07
10.27
10.04
10.91
Operating Margin (%)
155
242
260
281
310
365
385
401
426
488
499
500
503
514
558
670
735
Depreciation Expense
225
225
452
617
773
687
818
823
898
1,414
2,804
2,050
1,663
1,714
1,682
1,949
2,288
Net Income, GAAP
28.6
30.29
31.12
28.27
22.53
27.87
29.49
33.89
31.5
23.69
24.01
24.06
25.79
27.15
20.62
7.57
17.7
Effective Tax Rate (%)
4.53
3.41
5.48
6.36
7.06
6.06
6.84
6.62
5.75
7.83
13.01
8.24
6.15
6.83
7.1
7.73
8.03
Profit Margin (%)
-71
-101
172
-224
428
653
771
1,152
1,933
2,748
4,614
4,533
5,423
5,252
5,014
5,455
6,138
Working Capital
743
669
807
766
1,635
1,912
2,015
2,027
2,082
1,862
1,511
1,404
2,051
2,762
2,857
2,577
2,397
LT Debt
1,565
1,765
2,076
2,509
3,082
3,467
4,001
4,554
5,434
6,525
9,134
10,363
11,927
12,820
13,693
15,492
16,817
Total Equity
6.17
5.17
9.26
10.68
11.22
8.77
9.56
11.48
11.6
16.24
25.92
15.77
11.62
10.99
9.93
11.23
11.65
Return on Invested Capital (%)
8.73
8.75
12.88
14.81
15.5
12.66
12.57
11.21
11.41
15.98
25.84
15.53
11.3
10.73
10.27
11
11.92
Return on Capital (%)
15.08
13.49
23.56
26.92
27.64
20.99
21.91
19.24
17.97
23.65
35.81
21.03
14.92
13.86
12.69
13.36
14.53
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Mar'26
Jun'27
Sep'27
ST Debt
3,189
- -
3,799
LT Borrowings
2,569
- -
2,395
LT Finance Leases
9
- -
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
91
91
91
Market Capitalization
29,152
34,491
39,296

Working Capital

INR

•

in mil. unless spec.
Mar'26
Jun'27
Sep'27
Total Current Assets
14,678
- -
16,574
Cash, Cash Equivalents & STI
82
- -
258
Accounts Receivable, Net
8,299
- -
9,051
Inventories
4,908
- -
6,031
Total Current Liabilities
9,223
- -
10,436
Payables & Accruals
- -
- -
- -
ST Debt
3,189
- -
3,799
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.46%
11.2%
13.14%
Free Cash Flow
-226.21%
-166.95%
18.98%
Net Income, GAAP
15.59%
-5.74%
15.91%
Sales/Revenue/Turnover
8.77%
3.56%
6.43%
Total Cash Common Dividend
- -
7.35%
100.55%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
5,553
5,983
5,566
6,768
23,689
2026
5,905
6,528
6,017
7,203
25,213
2027
7,028
8,262
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
3.62
3.84
4.06
6.89
18.42
2026
5.91
4.96
4.44
6.05
21.36
2027
5.5
9.09
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
0.99
2026
- -
- -
- -
- -
1.99
2027
- -
- -
- -
- -
- -
Business
Aarti Drugs Limited manufactures active pharmaceutical ingredients, pharmaceutical intermediates, specialty chemicals, and formulations through its wholly-owned subsidiary Pinnacle Life Science Private Limited. The company produces APIs such as ciprofloxacin hydrochloride, metronidazole, metformin HCl, ketoconazole, and ofloxacin; pharmaceutical intermediates including fluoroquinolones and nitroimidazoles; and specialty chemicals such as salicylic acid, trimethylamine, dimethylamine, monomethylamine, benzene sulphonyl chloride, and methyl nicotinate. Founded in 1984 and headquartered in Mumbai, India, as part of the Aarti Group of Industries, Aarti Drugs operates 13 manufacturing facilities, primarily in Maharashtra including Tarapur and Sayakha, serving over 100 countries with approximately 50 API molecules and 80 finished products targeted at generic pharmaceutical sectors. The company pursues backward integration and capacity expansions, including the commissioning of its Sayakha amines plant in September 2025 to enhance raw material security for metformin production and scaling Tarapur salicylic acid output to 500 tonnes monthly by Q4 FY26. Aarti Drugs completed a share buyback of 6.65 lakh equity shares at Rs 900 each in September 2025, reducing paid-up capital to Rs 91.27 crore, and plans Rs 150-200 crore capex in FY26 for new product introductions and facility upgrades amid a focus on US and EU regulatory approvals for high-value API exports. These initiatives support double-digit revenue growth, as evidenced by Q2 FY26 results showing 9% year-over-year revenue increase to Rs 653 crore and 23% EBITDA rise to Rs 84 crore.